RESEARKA

Mechanistically, the rationale linking ARBs to longevity centers on mitigating pathological angiotensin II signaling, which contributes to inflammation, fibrosis, and organ damage, thereby theoretically slowing age-related decline. The mechanistic substrate underlying this potential benefit is supported by the broader evidence on RAAS inhibition in cardiovascular disease, which forms the biological plausibility for trials like the HFrEF polypill pilot (Agarwal 2025). This pilot trial protocol (Agarwal 2025) includes losartan, an ARB, as one component of a multi-drug intervention aimed at improving heart failure outcomes, which are a major determinant of mortality. The systematic review by Wang 2026 synthesizes evidence on several advanced heart failure therapies, positioning ARBs as part of a foundational treatment landscape where survival benefits are mediated through integrated cardiovascular protection (Wang 2026). The evidence therefore points to a context-dependent effect, where ARBs may contribute to longevity by reducing mortality in specific high-risk cardiovascular populations as part of comprehensive care (Jin 2025; Murray-Thomas 2025).

Citation Support

• source_1 Solomon 2026
• source_2 Din 2026
• source_3 Li 2025
• source_4 Mei 2025
• source_5 Chung 2024